Ladenburg Thalmann Financial Services’s Standard BioTools LAB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Sell	9 -63	-88%	-$222	﹤0.01%	5415
2019 Q3	$0	Sell	72 -1,666	-96%	-$13.1K	﹤0.01%	5364
2019 Q2	$21K	Buy	1,738 +110	+7%	+$1.4K	﹤0.01%	4024
2019 Q1	$21K	Buy	1,628 +1,074	+194%	+$11.3K	﹤0.01%	3963
2018 Q4	$5K	Buy	+554	New	+$4.32K	﹤0.01%	4595
2015 Q4	–	Sell	-2	Closed	–	–	4730
2015 Q3	$0	Buy	+2	New	+$31	﹤0.01%	4670

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ladenburg Thalmann Financial Services's LAB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Standard BioTools (LAB) stake by 88% in Q4 2019, selling an estimated $222 and leaving 9 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5415.

Ladenburg Thalmann Financial Services first reported a position in LAB in Q3 2015 and has held it in 6 quarters since. The position peaked at $21K in Q2 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Ladenburg Thalmann Financial Services held 9 shares of Standard BioTools worth $0 as of Q4 2019.
Ladenburg Thalmann Financial Services sold 63 Standard BioTools shares in Q4 2019, an estimated $222.
Standard BioTools made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5415 holding.
Ladenburg Thalmann Financial Services first reported a position in Standard BioTools in Q3 2015 and has held it in 6 quarters since.
Ladenburg Thalmann Financial Services's Standard BioTools position peaked at $21K in Q2 2019.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.